78 related articles for article (PubMed ID: 17072347)
21. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.
Chan DW; Liu VW; Tsao GS; Yao KM; Furukawa T; Chan KK; Ngan HY
Carcinogenesis; 2008 Sep; 29(9):1742-50. PubMed ID: 18632752
[TBL] [Abstract][Full Text] [Related]
22. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
23. LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation.
Dai HP; Xue YQ; Zhou JW; Li AP; Wu YF; Pan JL; Wang Y; Zhang J
Genes Chromosomes Cancer; 2009 Dec; 48(12):1027-36. PubMed ID: 19760607
[TBL] [Abstract][Full Text] [Related]
24. Tumor promoting properties of the ETS protein MEF in ovarian cancer.
Yao JJ; Liu Y; Lacorazza HD; Soslow RA; Scandura JM; Nimer SD; Hedvat CV
Oncogene; 2007 Jun; 26(27):4032-7. PubMed ID: 17213815
[TBL] [Abstract][Full Text] [Related]
25. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
[TBL] [Abstract][Full Text] [Related]
26. Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA.
Chinen Y; Taki T; Nishida K; Shimizu D; Okuda T; Yoshida N; Kobayashi C; Koike K; Tsuchida M; Hayashi Y; Taniwaki M
Oncogene; 2008 Apr; 27(15):2249-56. PubMed ID: 17968322
[TBL] [Abstract][Full Text] [Related]
27. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
[TBL] [Abstract][Full Text] [Related]
28. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
29. Identification and analysis of the human CD160 promoter: implication of a potential AML-1 binding site in promoter activation.
Schmitt C; Ghazi B; Bellier F; Bensussan A
Genes Immun; 2009 Oct; 10(7):616-23. PubMed ID: 19626042
[TBL] [Abstract][Full Text] [Related]
30. Alternative splice variant of actinin-4 in small cell lung cancer.
Honda K; Yamada T; Seike M; Hayashida Y; Idogawa M; Kondo T; Ino Y; Hirohashi S
Oncogene; 2004 Jul; 23(30):5257-62. PubMed ID: 15122314
[TBL] [Abstract][Full Text] [Related]
31. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
32. Expression of a splicing variant in the 5'-UTR of the human ERCC1 gene is not cancer related.
Winter AG; Dorgan C; Melton DW
Oncogene; 2005 Mar; 24(12):2110-3. PubMed ID: 15688021
[TBL] [Abstract][Full Text] [Related]
33. N34S mutation in the SPINK1 gene is not associated with alternative splicing.
Masamune A; Kume K; Takagi Y; Kikuta K; Satoh K; Satoh A; Shimosegawa T
Pancreas; 2007 May; 34(4):423-8. PubMed ID: 17446841
[TBL] [Abstract][Full Text] [Related]
34. Identification of three mouse mu-opioid receptor (MOR) gene (Oprm1) splice variants containing a newly identified alternatively spliced exon.
Doyle GA; Rebecca Sheng X; Lin SS; Press DM; Grice DE; Buono RJ; Ferraro TN; Berrettini WH
Gene; 2007 Feb; 388(1-2):135-47. PubMed ID: 17156941
[TBL] [Abstract][Full Text] [Related]
35. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array.
Gardina PJ; Clark TA; Shimada B; Staples MK; Yang Q; Veitch J; Schweitzer A; Awad T; Sugnet C; Dee S; Davies C; Williams A; Turpaz Y
BMC Genomics; 2006 Dec; 7():325. PubMed ID: 17192196
[TBL] [Abstract][Full Text] [Related]
36. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
37. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM
Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345
[TBL] [Abstract][Full Text] [Related]
38. Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines.
Escrevente C; Machado E; Brito C; Reis CA; Stoeck A; Runz S; Marmé A; Altevogt P; Costa J
Int J Oncol; 2006 Sep; 29(3):557-66. PubMed ID: 16865271
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer.
Cody NA; Shen Z; Ripeau JS; Provencher DM; Mes-Masson AM; Chevrette M; Tonin PN
Mol Carcinog; 2009 Dec; 48(12):1077-92. PubMed ID: 19347865
[TBL] [Abstract][Full Text] [Related]
40. Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.
Ottone T; Hasan SK; Montefusco E; Curzi P; Mays AN; Chessa L; Ferrari A; Conte E; Noguera NI; Lavorgna S; Ammatuna E; Divona M; Bovetti K; Amadori S; Grimwade D; Lo-Coco F
Genes Chromosomes Cancer; 2009 Mar; 48(3):213-21. PubMed ID: 19023877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
